Association Between the Use of Pulmonary Artery Catheter and Clinical Outcomes After Liver Transplantation

Seoul National University

Status: Enrolling

Conditions: Liver Transplant; Complications; Liver Cirrhosis; End Stage Liver DIsease; Liver Diseases

Treatments: Device: Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA); Device: FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)

Study type: Observational

Funder types: Other

Identifiers

NCT05457114

H-2205-117-1327

Details and patient eligibility

About

The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.

Full description

Pulmonary artery catheter (PAC) has been used for advanced hemodynamic monitoring during liver transplantation. However, recent advances in less invasive monitoring could provide continuous cardiac output monitoring by arterial waveform analysis. Using this technology, stroke volume variation (SVV) is monitored as a preload index. Calculated systemic vascular resistance (SVR) can be monitored if central venous pressure (CVP) is provided. Therefore, this less invasive form of hemodynamic monitoring may replace the PAC. The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.

Enrollment: 1,970 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2006 and 2022

Exclusion criteria

• Patients with baseline renal dysfunction
• Missing baseline or outcome variables
• Retransplantation
• Patients who received intraoperative transesophageal echocardiography (TEE) monitoring

Trial design

1,970 participants in 2 patient groups

Pulmonary artery catheter group

Description:

Patients who received pulmonary artery catheter insertion and hemodynamic monitoring by PAC-derived parameters

Treatment:

Device: Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)

Non-pulmonary artery catheter group

Description:

Patients who did not received pulmonary artery catheter insertion and were monitored with Flo-Trac FloTrac Vigileo

Treatment:

Device: FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)